Navigation Links
Smith & Nephew Endoscopy Launches the FOOTPRINT PK Suture Anchor for Shoulder Repair
Date:4/24/2008

Enables surgeons to adjust suture tension during bridging procedures

ANDOVER, Mass., April 24 /PRNewswire-FirstCall/ -- Smith & Nephew's (NYSE: SNN; LSE: SN) Endoscopy Division today announced the launch of the FOOTPRINT PK Suture Anchor, a system used to attach rotator cuff tissue to bone in the shoulder. The anchor is among products featured at the Arthroscopy Association of North America (AANA) Spring Meeting, which began today in Washington, D.C.

The objective during rotator cuff repair is to return the soft tissue to its original anatomic attachment site. Unlike early single row suture anchor techniques, which employed single-point re-attachment, the "footprint repair" approach uses multiple anchors in two rows, often with suture bridges that provide greater tissue-to-bone attachment (see attached).

Early approaches to cuff repair included transosseous tunnel repairs, which are still done today in some medical practices. During this procedure, the surgeon drills bone tunnels through the humeral head and laces suture through them. Smith & Nephew Endoscopy's FOOTPRINT PK Suture Anchor delivers a Transosseous Equivalent (TOE) repair without the need for drilling transosseous bone tunnels.

Its two-piece design allows for the shell of the anchor to be tapped into place. Then, independent of implantation, an inner plug is advanced, which secures the sutures running from the other anchor rows.

"The FOOTPRINT PK Suture Anchor enables surgeons to precisely apply the desired amount of suture tension that is necessary to maximize the construct strength on a case-by-case basis," said Dr. Nikhil Verma, an orthopaedic surgeon and sports medicine specialist at Midwest Orthopaedics at Rush University Medical Center
'/>"/>

SOURCE Smith & Nephew Endoscopy
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
2. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
3. Correction: Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Inverness Medical Innovations, Inc.
4. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
5. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Merck & Co., Inc. Who Invested in the Merck & Co., Inc. Employee Savings and Security Plan
6. GlaxoSmithKline Confirms Receipt of FDA Letter on Regulatory Reporting
7. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of WellPoint, Inc. Who Invested in the WellPoint Retirement Savings Plan
8. Former NYPD and Suffolk County Parks Officer, Who Responded to 9/11, to Receive Power Scooter From The SCOOTER Store at Benefit Event in Smithtown
9. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
10. Reps. Smith and Doyle, Autism Society of America Push Landmark Legislation on World Autism Awareness Day
11. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Negative Pressure Wound Devices Draw FDA Notice, Advice 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4EyeCare America Works to Prevent Blindness Caused by Cataracts 54141 1EyeCare America Works to Prevent Blindness Caused by Cataracts 54141 2EyeCare America Works to Prevent Blindness Caused by Cataracts 54141 3Community Hospital System Integrates Patient Data with Orion Health 54139 1Community Hospital System Integrates Patient Data with Orion Health 54139 2Community Hospital System Integrates Patient Data with Orion Health 54139 3Re Envision Your Look 3A Dr David Whiteman Suggests Breast Revision Surgery as Solution for Women Dissatisfied with Prior Procedures 54137 1Re Envision Your Look 3A Dr David Whiteman Suggests Breast Revision Surgery as Solution for Women Dissatisfied with Prior Procedures 54137 2Re Envision Your Look 3A Dr David Whiteman Suggests Breast Revision Surgery as Solution for Women Dissatisfied with Prior Procedures 54137 3